Research analysts at Zacks Research increased their Q3 2025 earnings estimates for shares of The PNC Financial Services Group ...

Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...

The Buccaneers and Falcons are fighting a pointless battle, the Commanders are all the way back, and more in our weekly NFL ...

Azure faces supply constraints and likely market share loss, and Microsoft's custom AI chip development lags behind ...

Read about the analyst's hold rating on PPC due to earnings uncertainty and potential downside with a buying opportunity seen ...

In this podcast, Motley Fool analyst Jim Gillies and host Ricky Mulvey discuss: A sporting goods retailer buying back a lot of stock. Aritzia's comeback year. Then, Motley Fool host Alison Southwick ...

Tidal Investments LLC lessened its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 51.6% during ...

We are expecting to get the La Niña rains. Ultimately we are optimistic and thinking that we may have a season of recovery – ...

His eldest had his own run-in with another of Yaakov’s wives. And, all his kids wanted his youngest dead. The axil that ...

Markets have witnessed several challenges in the recent past - Russia Ukraine war, the escalation of Israel Palestine ...

For the first time in over a decade, obesity rates in the United States may finally be heading in the right direction and new weight loss drugs like semaglutide could be part of the reason why. A ...